Search PubMed⌕ Search

Biomedical subjects

B Patsner

Publications and source records attributed to B Patsner.

At least 91 records · Page 5Linked to original sources
PubMed1988

Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma.

Serum CA 125 levels were measured preoperatively by standard radioimmunometric techniques in 89 patients with primary endometrial carcinoma before definitive surgical staging and resection. Fifty-seven of 58 (98%) patients with clinical and surgical Stage I or II disease had normal preoperative serum CA 125 levels. All eight patients with clinically advanced endometrial cancer (International Federation of Gynecology and Obstetrics Stage III or IV) had elevated CA 125 levels before surgery. Twenty of 23 patients (87%) with clinical Stage I or II endometrial cancer who were found to have extrauterine spread of disease during staging laparotomy had elevated preoperative serum CA 125 levels. Thus preoperative CA 125 levels were elevated in 28 of 31 patients (90.3%) with surgically staged endometrial adenocarcinoma with extrauterine disease and may play a useful role in detecting those patients with clinically localized endometrial cancer who have occult extrauterine spread of disease.

Adenocarcinoma↗
PubMed1988

Comparison of serum CA-125 and lipid-associated sialic acid (LASA-P) in monitoring patients with invasive ovarian adenocarcinoma.

Twenty-seven patients with frankly invasive nonmucinous invasive adenocarcinoma of the ovary were monitored using a serial CA-125 and lipid-associated sialic acid (LASA-P) levels prior to cytoreductive surgery, during chemotherapy, before second-look surgery or disease progression, and during subsequent follow-up. All levels were measured using previously described techniques. Serum LASA-P levels correlated well with CA-125 levels during all phases of treatment with no significant difference in predictive value of elevated or normal levels. LASA-P levels, thus, offer another, possibly less expensive, method of monitoring patients with invasive ovarian adenocarcinoma during therapy and in predicting the likelihood of a positive second-look laparotomy.

Adenocarcinoma↗
PubMed1988

The value of preoperative serum CA 125 levels in patients with a pelvic mass.

Serum CA 125 measurements were obtained before operation in 250 consecutive patients admitted with the diagnosis of a pelvic mass. We examined and operated on all patients. Elevated preoperative serum CA 125 levels were more predictive of malignancy in postmenopausal than in premenopausal women (0.86 vs 0.67), but normal levels did not preclude malignancy in either group. Possible limitations of routine measurement of serum CA 125 in the work-up of patients with a pelvic mass are discussed.

Antigens, Tumor-Associated, Carbohydrate↗
PubMed1988

Treatment of metastatic lipid cell tumor of the ovary with BV-CAP and VAC chemotherapy, using serum testosterone and dihydrotestosterone as tumor markers.

A metastatic ovarian lipid cell tumor was treated with BV-CAP chemotherapy following cytoreductive surgery and VAC chemotherapy for persistent disease found at second-look laparotomy before disease progression was noted. Serum Dihydrotestosterone (DHT) levels correlated with disease status during all phases of treatment, as did serum testosterone (T) to a lesser degree. Measurement of these two hormones may provide additional useful information on the response of patients with subclinical metastatic disease to post-operative therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

Ureteral injuries in an obstetrics and gynecology training program: etiology and management.

Between July 1980 and September 1987, 3185 major gynecologic operations were performed in our residency program. Ureteral injury occurred in 17 cases, 14 of which (0.4%) were accidental. In 16 cases, the injury was noted intraoperatively and repaired primarily; one injury was repaired after identification on the fourth postoperative day. Large pelvic masses, which limited exposure, and tumor invasion of the parametrium contributed to ureteral injury. Preoperative intravenous pyelogram or computed tomography did not prevent ureteral damage. Sixteen ureteroneocystostomies were performed with good result. One ureteroureterostomy leaked, but healed over a percutaneous stent without problems. All patients subsequently had normal renal function.

Aged↗
PubMed1987

Ovarian metastases from stage IB adenocarcinoma of the cervix.

At the time carcinoma of the cervix is treated by radical surgery, it is believed that ovarian preservation is possible, and will prevent surgical menopause, with its risks of osteoporosis, vaginal dryness, and "hot flashes." However, the data originally used to justify ovarian preservation was based on clinical experience with squamous cell carcinoma of the cervix. Little if any data exist to justify this treatment rationale in patients with adenocarcinoma of the cervix. Two patients who presented with clinical Stage IB adenocarcinoma of the cervix, subsequently underwent radical surgical treatment. Pathologic review of the operative specimens revealed microscopic metastasis to the ovaries in both patients. It is suggested that ovarian preservation at the time of radical surgical treatment for adenocarcinoma of the cervix has not had its safety established, and that sacrificing the ovaries and providing hormonal replacement postoperatively may be a safer course.

Adenocarcinoma↗
PubMed1987

Predictive value of CA-125 levels in advanced ovarian cancer.

Thirty-eight patients with advanced ovarian cancer were monitored with serial serum CA-125 levels until second-look laparotomy or disease progression. Eleven of 15 patients had normal CA-125 levels but positive findings at second-look operation; two had normal levels despite progression of disease. Normal levels do not reliably predict absence of disease.

Antigens, Neoplasm↗
PubMed1987

1.5-5 years of uninterrupted cis-diamminedichloroplatinum II chemotherapy for metastatic cervical cancer.

In an attempt to prolong remission duration in patients with metastatic cervical cancer to cis-platinum based chemotherapy, patients were treated on an every other month basis after a minimum of 1 year of cis-platinum based chemotherapy. To date, five patients have received 5, 4.5, 2.3, 2.3, and 1.5 years, respectively, of uninterrupted cis-platinum based chemotherapy. All remain in complete remission after receiving a total dose of cis-platinum of 2523 mg (1530 mg/m2), 2.408 mg (1655 mg/m2), 1496 mg (880 mg/m2), 1325 mg (970 mg/m2), and 1640 mg (950 mg/m2), respectively. The only apparent toxicity has been asymptomatic hypomagnesemia. In contrast, three other patients in complete remission on cis-platinum based chemotherapy voluntarily discontinued such therapy and have subsequently developed uncontrolled recurrent cervical cancer. It is concluded that patients in complete remission from cis-platinum chemotherapy for metastatic cervical cancer can receive long-term cis-platinum based chemotherapy and that such therapy appears to be without significant toxicity.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

Cervical and vaginal pathology in women with vulvar condylomata.

All women referred to the Department of Obstetrics and Gynecology, School of Medicine, State University of New York at Stony Brook, for evaluation of vulvar condylomata were reviewed to identify concurrent cervical and vaginal pathology. Over the five-year period 1981-1985, referrals to our colposcopy clinic for vulvar condylomata increased from 7.8% to 29.2%. All patients underwent a thorough history, physical examination and colposcopic evaluation of the cervix, vulva and vagina. Of the patients with vulvar condylomata, 68% had biopsy-proven cervical and vaginal pathology. While 50% of patients with cervical disease had human papillomavirus infection alone, the other 50% had concurrent cervical intraepithelial neoplasia (CIN) or CIN only. Proper evaluation of patients with vulvar condylomata must include colposcopy of the cervix and vagina.

Cervix Uteri↗
PubMed1986

cis-Diamminedichloroplatinum plus dimethyl-triazenoimidazole carboxamide as second- and third-line chemotherapy for sarcomas of the female pelvis.

From 1981 to 1984, 20 patients with sarcomas of the female pelvis were treated with dimethyl-triazeno-imidazole carboxamide (DTIC) combined with cis-diamminedichloroplatinum II (DDP) in two sequential studies. Group 1 patients received low-dose (1 mg/kg) DDP plus DTIC; Group 2 patients received high-dose DDP (20 mg/m2 daily for 5 days) plus DTIC. Each regimen was repeated every 4 weeks depending on the patient and bone marrow tolerance. Of the 20 patients, 35% achieved an objective response. Of the 10 group 1 patients, 20% had an objective response (1 CR, 1 PR) both as second-line chemotherapy. For the group 2 patients, 50% (5) have responded (3 CR, 2 PR), one as third-line and 4 as second-line chemotherapy. These results suggest that DTIC plus DDP, especially at the higher dose (20 mg/m2 X 5), is effective chemotherapy for metastatic pelvic sarcomas.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

Stage II invasive adenocarcinoma of the ovary: results of treatment by whole abdominal radiation plus pelvic boost versus pelvic radiation plus oral melphalan chemotherapy.

Thirty-one patients with histologically confirmed FIGO Stage II adenocarcinoma of the ovary were prospectively treated in two sequential studies: 3000 rad of whole abdominal radiation therapy over 6 weeks by an open field technique followed by 2000 rad pelvic boost over 2 weeks (group 1, 16 patients, 1972-1974) or 5000 rad of pelvic radiation therapy over 5 weeks followed by a year of melphalan chemotherapy at a dose of 0.2 mg/kg/day for 5 days every 4 weeks (group 2, 15 patients, 1975-1982). Abdominal radiation included the entire peritoneal cavity and both diaphragms; the liver was not shielded. Only 2 patients had residual disease greater than 2 cm. No group 1 patients underwent pretherapy restaging laparoscopy prior to radiation or second look laparotomy after treatment. Eighty percent of group 2 patients underwent restaging laparoscopy (10) or staging laparotomy (2) prior to radiation. All group 2 patients underwent second look procedures if no evidence of disease. No patient developed intestinal complications secondary to radiation requiring surgery. Eighty-one percent of group 1 patients and to date 40% of group 2 patients developed recurrences. Size of residual disease prior to radiation, histologic grade, and substage (IIA, B, or C) did not correlate with recurrences. Five-year estimated survival was 40 and 50% for groups 1 and 2, respectively. Three thousand rad of wole abdominal radiation plus 2000 rad pelvic boost or 5000 rad pelvic radiation plus melphalan did not appear to improve survival over surgery alone. The role of radiation therapy in Stage II ovarian cancer remains unclear.

Adenocarcinoma↗
PubMed1986

Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma.

Fifty consecutive patients with recurrent and metastatic endometrial carcinoma were treated with melphalan, 5-fluorouracil, and medroxyprogesterone acetate with or without tamoxifen as first-line chemotherapy. The objective response rate was 48%, with 20% complete responses. The estimated median progression-free survival time was only five months (0.5 to 65 months) with estimated two- and five-year progression-free survival rates of 16 and 13%, respectively. The estimated median progression-free survival time was 24 months for complete responders; the progression-free survival times were significantly longer than the survival times (median = four months) for all other patients (P = .0002). Whether or not the addition of cytotoxic chemotherapy to progesterone hormonal therapy for metastatic endometrial carcinoma lengthens survival time is still open to question.

Adult↗
PubMed1985

Small cell carcinoma of the ovary: a rapidly lethal tumor occurring in the young.

Two patients with metastatic small cell carcinoma of the ovary managed by the Clinical Gynecologic Oncology Service at Roswell Park Memorial Institute are presented. Despite intensive multimodal therapy after extensive cytoreductive surgery, both patients expired from this rare tumor within 6 months of diagnosis. Neither tumor was associated with hypercalcemia, previously reported in the only existing review of the tumor in the world literature. Because of the highly aggressive nature of this cancer, effective combination chemotherapy must be found if the natural history of this tumor is to be altered.

Adolescent↗